Addex Trading Update: Completes 2018 with Strong Cash

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
23
Addex Trading Update: Completes 2018 with Strong Cash Position

Geneva, Switzerland, 7th January 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has completed the year 2018 with CHF41.7 million of cash and cash equivalence, and a net operating cash inflow of CHF1.8 million.

“Our positive operating cash performance was primarily driven by cash inflows from our partnership with Indivior and our strengthened cash position from our CHF40 million capital increase in March 2018,” said Tim Dyer, CEO of Addex. “For 2019, our focus continues to be the initiation of registration studies for dipraglurant in patients with Parkinson’s disease levodopa induced dyskinesia (PD-LID) and delivering on our funded research collaboration with Indivior, as well as pursuing additional collaborative arrangements accross our allosteric modulator portfolio.”

Financial Update

  • Cash and cash equivalents at 31 December 2018 of CHF41.7 million
  • Cash inflows from licensing, collaborations and grant providers of CHF6.4 million
  • Cash used in operations of CHF4.6 million, in line with expections
  • Net proceeds from capital increase of CHF37.5 million

Pipeline & Operating Update

  • Dipraglurant: solid progress made to start pivotal registration studies in H2 2019 for the treatment of dyskinesia associated with Parkinson’s disease – manufacturing and CRO selection ongoing
  • Janssen partnership: continuing to work with our partner to advance ADX71149 into a proof of concept study in epilepsy
  • Indivior partnership: delivering on plans to enter phase 1 with lead candidate, ADX71441 during Q2 2019
  • GABAB PAM: novel candidates identified and progressing into preclinical characterization in models of addiction and Charcot-Marie-Tooth type 1A neuropathy
  • Discovery programs: mGluR4PAM, mGluR3PAM, mGluR7NAM and TrkB PAM making significant progress in lead optimization
  • Team Expansion: progressing according to plan with 17 full time equivalents at end of 2018.

Upcoming Financial Reports

  • 11 March 2019 - Full-year financial results and publication of the Annual Report
  • 31 July 2019 – Half-year 2019 financial results

About Addex Therapeutics

Addex Therapeutics ( www.addextherapeutics.com ) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex' allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline has been generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated. Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) program was awarded a $5.3 million grant by the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) to support human studies in cocaine addiction and has been licensed to Indivior. Discovery programs include mGluR4PAM, mGluR7NAM, mGluR3PAM and TrkBPAM.

Press Contacts: For Addex Therapeutics

Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 Email: PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)20 7318 2955 msinclair@halsin.com

Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 64

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 68

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Senior Living: The BrainFit Gym Experience

Updated Category News Views 330

Introducing the BrainFit Gym at The Bristal The Bristal Assisted Living is taking a bold step towards promoting cognitive wellness among seniors with their newly launched BrainFit Gym. Located at The Bristal at York Avenue, this unique facility stands out as a pioneering initiative aimed at enhancing the mental capacities of its residents. With this innovative approach,...

Continue Reading
Bullish (BLSH) Stock Surges After Thrilling IPO Success

Updated Category News Views 262

Bullish Stock Makes a Remarkable Entrance on the Market Recently, the cryptocurrency exchange Bullish (BLSH) took the public market by storm with its much-anticipated initial public offering (IPO). Its shares soared following trading debut, generating excitement among investors and analysts alike. Key Highlights of the IPO Supported by the renowned billionaire venture...

Continue Reading
Medius Honored as Top Microsoft Partner for Innovative Finance

Updated Category News Views 118

Medius Named 2024 Microsoft ISV Partner of the Year Medius, a leader in Accounts Payable (AP) Automation and Spend Management solutions, has reached an impressive milestone by being honored as the 2024 Microsoft ISV Partner of the Year. This esteemed award showcases Medius' dedication to innovation and excellence in improving finance operations through technology. The...

Continue Reading
Day One Biopharmaceuticals Set to Reveal Q1 2025 Financials

Updated Category News Views 309

Day One Biopharmaceuticals Plans Q1 2025 Financial Report Day One Biopharmaceuticals (NASDAQ: DAWN) is gearing up for a significant event. The biopharmaceutical company, known for its dedication to developing targeted therapies for serious illnesses, has announced a live conference call and webcast set for early May 2025. This event offers a chance for stakeholders to...

Continue Reading
Navigating the Future of Nonprofit Fundraising in 2025

Updated Category News Views 441

Nonprofit Fundraising Trends for 2025 As we approach the year 2025, nonprofits are setting their sights on innovative tactics that will not only enhance their fundraising efforts but also embrace the changing dynamics of donor engagement. Recent insights reveal that the landscape of nonprofit fundraising is evolving, making adaptability a core component of success in the...

Continue Reading